Friday, January 13, 2006
Tamiflu (generic name: Oseltamivir) a common antiviral drug used in the treatment and prophylaxis of both Influenza virus A and Influenza virus B, will be marketed in a generic form in India. It is a prodrug, which is hydrolysed hepatically to the active metabolite, the free carboxylate of oseltamivir. It was developed by Gilead Sciences and is currently marketed by Hoffmann-La Roche (Roche) under the trade name Tamiflu.
Cipla received marketing approval from the drug controller-general of India and will launch a generic version of Oseltamivir, Anti-Flu, in the domestic market this month. The drug will be priced at about Rs 1,000 per strip of 10 75 mg tablets, which is less than half the current Tamiflu market price of $60. The required dosage is two tablets every day during five days.